Pharmacological management of atrial arrhythmias

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDepartment of Pharmacology and Pharmacotherapyhu_HU
dc.contributor.authorKure, Saadatu Ibrahim
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2020-10-15T09:52:08Z
dc.date.available2020-10-15T09:52:08Z
dc.date.created2019-04-26
dc.description.abstractThis issue provides a clinical overview of atrial arrythmias, focusing on their pharmacological management which has developed diversely over the last decades. Atrial fibrillation (AF) is the most common arrhythmia diagnosed in clinical practice. Rhythm and rate strategies are considered equivalent for the management of atrial fibrillation (AF). Moreover, both strategies are intended for improving symptoms and quality of life. There are mostly channel blockers affecting the sodium and potassium channels to prevent rhythm generation or delay its propagation. Maintaining a heart rate of 60-80 bpm at rest or < 115 during exercise is essential for normal body function. The ventricular heart rate control is done using drug categories such as beta blockers, calcium channel blockers, cardiac glycosides and others.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent46hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/296785
dc.language.isoenhu_HU
dc.subjectatrial arrhythmiashu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titlePharmacological management of atrial arrhythmiashu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)